

**Original Research Article** 

 Received
 : 28/05/2023

 Received in revised form
 : 01/07/2023

 Accepted
 : 13/07/2023

Keywords: Stroke, Sickle Cell anaemia, Sickle Cell Disease.

Corresponding Author: **Dr. Soumya ranjan Meher,** Email: soumyacare4u@gmail.com

DOI: 10.47009/jamp.2023.5.4.104

Source of Support: Nil, Conflict of Interest: None declared

*Int J Acad Med Pharm* 2023; 5 (4); 511-515



# WITH SICKLE CELL ANAEMIA A CASE CONTROL STUDY

Susant Kumar Behera<sup>1</sup>, Sitanshu kumar Meher<sup>2</sup>, Juturu Naveen Kumar<sup>3</sup>, Soumya ranjan Meher<sup>4</sup>

<sup>1</sup>Assistant Professor, Department of Pediatrics, Veer Surendra Sai Institute of Medical Sciences and Research, BURLA, Odisha, India.

<sup>2</sup>Associate Professor, Department of Pediatrics, Veer Surendra Sai Institute of Medical Sciences and Research, BURLA, Odisha, India.

<sup>3</sup>Senior Resident, Department of Pediatrics, Veer Surendra Sai Institute of Medical Sciences and Research, BURLA, Odisha, India.

<sup>4</sup>Senior Resident, Department of Pediatrics, Veer Surendra Sai Institute of Medical Sciences and Research, BURLA, Odisha, India.

### Abstract

Background: Sickle cell anemia and disease is the common burden of western Odisha. Cerebrovascular disease, particularly stroke, is one of the most severe clinical complications associated with sickle cell disease and is a significant cause of morbidity in both children and adults. Hense predicting the risk of stroke by searching the most common risk factors associated with SCD with stroke may decrease the morbidity and mortality due to stroke. Materials and Methods: we conducted a case control study in department of pediatrics, VIMSAR, Burla from November 2019 to September 2021 a retrospective study after institutional ethics committee approval.we had included 74 subjects as per predefined inclusion and exclusion criteria .cases were defined as HPLC confirmed cases of sickle cell anemia and disease and had a stroke and controls are HPLC confirmed cases of SCD/SCA and without any history of stroke and socio demographic variables like increasing age, gender ,socioeconomic status and clinical history variables like Number of hospitalizations, frequency of anemia, ACS , VOC , frequency of BT and laboratory variables like Hb, RC, MCV, MCH, MCHC, WBC, and HPLC variables like HbA2, HbF, HbS are studied and analyzed in both groups. Results: Out of total 2263 sickle cell patients visited to pediatric OPD& IPD, VIMSAR, BURLA. Total 37 patients were had stroke and remaing doesn't had stroke and among cases variables like socio demographic variables like increasing age, male gender 44 (59.5%), socioeconomic status and clinical history variables like family history of stroke ((48.48%) increased Number of hospitalizations 6-10 27(73.0%) , increased frequency of anemia ,ACS 23(62.2%), increased VOC > 5 28(75.7%), increased frequency of BT 8-10 33 (89.2%) and laboratory variables like decreasesed Hb, increased RC(%), MCV,MCH,MCHC, increased WBC are clinically and statistically significant and HPLC variables like HbA2, HbF, HbS are clinically significant but statistically insignificant. Conclusion: The absence of uniformity and standardization in the definition of distinct CVD events (ischemic stroke, TIA, hemorrhagic stroke, silent infarcts, vascular stenosis detected by MRA, and moya-moya disease) makes the interpretation and comparison of study results difficult and is probably a major factor that explains the controversies.

# **INTRODUCTION**

Stroke is a well-recognised complication of homozygous sickle cell anaemia (SCA; haemoglobin SS-HbSS) and also occurs in compound heterozygotes, e.g., those with HbSC disease and HbSβthalassaemia (HbSβthal).<sup>[1]</sup> Sickle

cell anaemia (SCA) is the most common cause of childhood stroke, occurring with the highest frequency before the age of 6 years.<sup>[2]</sup> Despite the relative frequency of stroke in SCA, few predictors of risk exist. Anaemia, leucocytosis, hypertension, silent infarction, and history of acute chest syndrome are well-documented risk factors for ischaemic stroke in SCA. Recent data suggest that other environmental and genetic factors, many unrelated to SCA, influence the development of cerebrovascular disease.<sup>[3]</sup>

There are data on the epidemiology of stroke in SCD from cohort studies, records of patients enrolled in healthcare provision, discharge data from hospitalisations and treatment trials. A major difficulty is the lack of information about diagnostic criteria for inclusion.<sup>[4]</sup> Earlier studies used definitions which were not necessarily standardised and, although more recent studies have included neuroimaging, as well as using the World Health Organisation definition of stroke, there is little evidence of neurological or neuroradiological overreading or of the inclusion/exclusion criteria applied.<sup>[5]</sup> In fact, there is a wide differential of focal and generalised vascular and non-vascular pathologies, often distinguished using acute MR techniques, with important management implications.<sup>[6]</sup>

Acute neurological symptoms and signs are common in SCD and, as well as stroke, include transient ischaemic attack (TIA), headaches, seizures and coma.<sup>[7]</sup> Altered mental status with or without reduced level of consciousness, headache, seizures, visual loss or focal signs can occur in numerous contexts, including infection, acute chest syndrome (ACS), acute anaemia, after surgery, transfusion or immunosuppression and apparently spontaneously.<sup>[8]</sup> For example, in one large series of patients with SCD and ACS, 3% of patients had neurological symptoms at presentation, and these symptoms developed in a further 7–10% as a complication of ACS.<sup>[9]</sup>

# **MATERIALS AND METHODS**

This is a Unmatched Case Control Study was conducted in Veer Surendra Sai Institute of Medical Sciences and Research, Burla. The study settings were at the IPD and OPD of Department of Paediatrics and the Sickle Cell Institute of VIMSAR, Burla with Global positioning as follows.

Sickle cell anemia children HbSS attending our OPD / IPD for any cause.

#### Inclusion Criteria

- 1. All Sickle cell homozygous HPLC diagnosed children
- 2. Sickle cell patients diagnosed as stroke.
- 3. With age group below 14 years.
- 4. Either gender.

Exclusion Criteria not required

Automated high performance liquid chromatography (HPLC)

HPLC has four advantages over electrophoresis in diagnosing sickle disorders.

- 1. The analyzers are automated and thus utilize less time and permit Processing of large batches.
- 2. Very small samples (5pl) are sufficient for analysis; this is especially needful for pediatric patients.
- 3. Quantification of normal and variant hemoglobin is available on every sample.
- 4. A provisional identification of large proportion of variant hemoglobin can be made.

## Data Analysis and Interpretation

Data collected from the study was processed, checked for internal errors, internal and external validation was done using n Master Version 2.0 software and SPSS v 25 software. Data was analyzed and the result was interpreted.

# **RESULTS**

Table 1: showing that out of total 74 homozygous sickle subjects significant proportion of study population are in the age group of 7-10 years 37 (50.0%) followed by 1-6 years of age 26(35.1%) and mostly males children 44 (59.5%).

ble 1: Sociodemographic profile of the study participants		
	Overall (N=74)	
Age		
1-6 yrs	26 (35.1%)	
7-10 yrs	37 (50.0%)	
10-14 yrs	11 (14.9%)	
Sex		
Male	44 (59.5%)	
Female	30 (40.5%)	

Table 2: Baseline Sociodemographic and Clinical Charecterestics of Study Population Mean

Charecterestics	Mean (SD)
Age ( years )	6.75(3.07)
Weight (kilograms)	18.71(5.29)
Height( centimeters)	96.24(13.68)
Number of blood transfusions	6.74(2.21)
Number of hospitalisations	6.837(1.81)
Number of acute chest syndrome	0.36(0.48)
Number of vaso occlusive crisis	5.337(2.50)
Reticulocyte count (%)	5.83(3.188)
Hemoglobin(g/dl)	6.20(1.41)
Packed cell volume (%)	42.97(2.82)
Mean corpuscular volume (fl)	35.59(8.37)

Mean corpuscular hemoglobin (pg)	34.28(4.24)
Mean corpuscular hemoglobin concentration (g/dl)	35.94(8.13)
Total platelet count (lakhs)	1.96(0.42)
HbS(%)	67.14(11.2)
HbF(%)	5.1(2.46)
HBA2(%)	1.86(0.48)
White blood cell count /mm <sup>3</sup>	12529.8(4976.3)

Table 2 Shows mean and standard deviation of the baseline clinical charecterestics of study population both cases and controls.

	Case (N=37)	Control (N=37)	Total (N=74)	P value
BP				0.16
70-90	14 (37.8%)	20 (54.1%)	34 (45.9%)	
>91	23 (62.2%)	17 (45.9%)	40 (54.1%)	
MRA				<0.001
ACA	7 (18.9%)	0 (0.0%)	7 (9.5%)	
MCA	26 (70.3%)	0 (0.0%)	26 (35.1%)	
Ν	0 (0.0%)	37 (100.0%)	37 (50.0%)	
PCA	4 (10.8%)	0 (0.0%)	4 (5.4%)	
RC				<0.001
<5%	6 (16.2%)	27 (73.0%)	33 (44.6%)	
>5%	31 (83.8%)	10 (27.0%)	41 (55.4%)	
Hb				<0.001
<6	30 (81.1%)	5 (13.5%)	35 (47.3%)	
>6	7 (18.9%)	32 (86.5%)	39 (52.7%)	
PCV				0.02
<35	22 (59.5%)	12 (32.4%)	34 (45.9%)	
>35	15 (40.5%)	25 (67.6%)	40 (54.1%)	
MCV				0.79
<50	2 (5.4%)	1 (2.7%)	3 (4.1%)	
50-75	22 (59.5%)	24 (64.9%)	46 (62.2%)	
76-90	13 (35.1%)	12 (32.4%)	25 (33.8%)	
MCH				<0.001
<35	9 (24.3%)	27 (73.0%)	36 (48.6%)	
>35	28 (75.7%)	10 (27.0%)	38 (51.4%)	
MCHC				<0.001
<35	8 (21.6%)	31 (83.8%)	39 (52.7%)	
>35	29 (78.4%)	6 (16.2%)	35 (47.3%)	
TPC				1
1-2.5	20 (54.1%)	20 (54.1%)	40 (54.1%)	
2.6-3.5	15 (40.5%)	15 (40.5%)	30 (40.5%)	
>3.5	2 (5.4%)	2 (5.4%)	4 (5.4%)	
WBC				<0.001
<10,000	10 (27.0%)	27 (73.0%)	37 (50.0%)	
>10,000	27 (73.0%)	10 (27.0%)	37 (50.0%)	

#### Table 4: Baseline Socio Demographic and Clinical Variables in Cases and Controls with Mean and P- Value

Variables	Sickle cell disease with stroke (n=37)	Sickle cell disease without stroke (n=37)	Pvalue	
Age ( years )	7.24 (2.58)	6.27(3.42)	< 0.001	
Weight (kilograms)	19.9(4.63)	17.4(5.67)	0.016	
Height( centimeters)	99.9(13.9)	92.5(12.5)	0.97	
Number of blood transfusions	8.35(1.2)	5.13(1.78)	< 0.001	
Number of hospitalisations	7.48(1.07)	6.18(2.15)	< 0.001	
Number of acute chest syndrome	0.62(0.49)	0.108(0.3)	< 0.001	
Number of vaso occlusive crisis	6.54(2.19)	4.13(2.22)	< 0.001	
Reticulocyte count (%)	7.54(2.84)	4.13(2.56)	< 0.001	
Hemoglobin(g/dl)	4.729(1.938)	7.67(2.10)	< 0.001	
Packed cell volume (%)	39.75(12.78)	46.18(10.6)	0.02	
Mean corpuscular volume (fl)	32.13(7.39)	39.05(7.93)	0.79	
Mean corpuscular hemoglobin (pg)	33.02(7.18)	35.54(14.64)	< 0.001	
Mean corpuscular hemoglobin concentration (g/dl)	33.16(7.18)	38.72(8.16)	< 0.001	
Total platelet count (lakhs)	1.95(0.4)	1.97(0.399)	1	
HbS(%)	67.29(10.85)	67(11.68)	0.87	
HbF(%)	5.37(2.37)	4.83(2.56)	0.82	
HBA2(%)	1.84(0.53)	1.87(0.42)	0.81	
White blood cell count /mm3	12931.9(4948.68)	12127.7(5039.2)	< 0.001	

Table 4: shows mean and standard deviation of various variables among both cases and controls showing age ,number of blood transfusions, number of vaso occlusive crisis, and reticulocyte count ,hemoglobin, packed cell volume and MCV, MCH, MCHC and WBC count showing significance.

Table 5: Association of Number of blood transfusions and stroke				
Study groups	≤4	Number of Blood transfusion (5-7)	10-Aug	Pvalue
SCD with stroke n=37	0	4 (10.8%)	33 (89.2%)	< 0.001
SCD without stroke n=37	20(54.05%)	14 (37.8%)	3 (8.1%)	

Table 5. shows frequency of blood transfusion among study population showing total 36 subjects received 8-10 (48.6%) blood transfusions among 74 patients and 18 (24.3%) received 5-7 blood transfusions and 20 subjects (27.02%) blood transfusions. Increased frequency of blood transfusions was observed in cases than controls and it is also significant with Pvalue <0.001.

## **DISCUSSION**

The study involved 74 cases of sickle cell disease and of which 44 ( 59.5%) were male and 30 ( 40.5% ) were females .Male to Female ratio 1.46:1. With male preponderance 44 (59.5%). But studies done by Domingos.<sup>[10]</sup> and Sarnaik et.<sup>[11]</sup> showed little female preponderance than male this may be due to little more male preponderance may be due to different geographical areas and different study populations.

The prevalence of stroke in children with sickle cell anemia is 3.75%.<sup>[12]</sup> .Risk of stroke is highest during first decade of life, drops in second decade and rises again from the beginning of third decade .

STOP data study by Hsu et al.<sup>[13]</sup>, cohort study by Rees et al.<sup>[14]</sup>, BABY HUG DATA by Pavlakis et al.<sup>[15]</sup>, cross sectional studies by Cox et al.<sup>[16]</sup> all these studies reported that steady low level haemoglobin associated with increased risk of stroke but none mentioned about the mean low value of haemoglobin value.

Kirkham et al.<sup>[17]</sup> a cohort study among homozygous sickle cell children shows increased haemoglobin levels are associated with increased risk. Kwiatkowski et al.<sup>[18]</sup> shown that increased Hb is also a protective factor for stroke.

In our study we found that among cases the mean haemoglobin was  $4.729(\pm 1.938)$  and among controls it was  $7.67 \ (\pm 2.10)$  showing less haemoglobin in cases than controls which is supported by the above studies . which was significant with P value of < 0.001.

Cohort study conducted by Meier et al.<sup>[19]</sup> & cross sectional study done by silva et al.<sup>[20]</sup> & cohort study conducted by Belisario et al.<sup>[21]</sup> & cohort study conducted by Bernaudina et al 22 shown that increased recticulocyte count % associated significantly with stroke in SCD children .

In our study also we found that more increased reticulocyte was observed in cases than in controls. reticulocytosis (>5%) with P value <0.001 has significantly associated with stroke in SCD. among subjects with reticulocyte count >5% 41,31 (75.6%) had stroke & 10 (24.3%) are without stroke.

Cohort study conducted by Lagunju et al.<sup>[23]</sup> & cohort study conducted by Adams et al.<sup>[24]</sup> shown that decreased hematocrit is associated with increased risk of stroke . And cohort study conducted by Miller et al 25 shown that increased hematocrit is associated with increased risk of stroke In our study we found mean value of Hematocrit was 39.75 (12.78) among cases and ampng controls it was 46.18 (10.6) both of which are within the normal reference range . but lower hematocrit values were observed in cases than the controls.

# **CONCLUSION**

In our study we found that clinical history findings like increasing age, and family history of sickle cell anemia ,and acute chest syndrome increased frequency of blood transfusions and vaso-occlusive crisis, hopsitalisations, blood transfusions are associated with significant increases in risk of stroke. And laboratory findings like decreased steady state hemoglobin level, and increased steady reticulocyte count % and increased MCH,MCHC WBC count are associated and increased significantly with increased stroke risk. And when comes to sickling history and HPLC parameters of study subjects values of HbS%, HbF%, HbA2% was not associated significantly statistically.

## REFERENCES

- 1. Quinn CT.Sickle cell disease in childhood:from newborn screening through transition to adult medical care.PediatriClin North Am.2013;60(6):1363-81.
- 2. Stuart MJ,Nagel RL.Sickle-cell diseasancet.2004;364(9442):1343-60
- Steinberg MH.Management of sickle cell disease.N Engl J Med.1999;340(13):1021-30.
- 4. Steinberg MH.Sickle cell anemia,the first molecular disease;overview of molecular etiology,pathophysiology,and therapeutic approaches.Sci World J.2008;8:1295-324.
- 5. Text book of Harrisson
- Enninful-Eghan H, Moore RH,Ichord R,Smith-Whitley K, Kwiatkowski JL.Transcranial Doppler ultrasonography and prophylactic transfusion programme if effective in preventing overt stroke in children with sickle cell disease .J Peditr.2010; 157(3):479-484.
- 7. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of transcranial Doppler screening and intensive therapy on cerebral

vasculopathy outcome in a newborn sickle cell anemia cohort.Blood.2011;117(4):1130-1140.quiz 1436.

- Hulbert ML,McKinstry RC,Lacey JL, et al.Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease .Blood. 2011; 117(3):772-9.
- Arnstrong FD, Thompson RJ Jr,Wang W,et al.Neuropsychology Committee of the cooperative study of sickle cell Disease .Cognitive function and brain imaging in children with sickle cell disease.Pediatrics. 1996;97(6, pt 1);864-70.
- Domingos IF, Falcao DA, Hatzlhofer BL, Cunha AF, Santos MN, Albuquerque DM, et al. Influence of the beta haplotype and alpha-thalassemia on stroke development in a Brazilian population with sickle cell anaemia. Ann Hematol. 2014;93(7):1123–9. 80.
- Sarnaik SA, Ballas SK. Molecular characteristics of pediatric patients with sickle cell anemia and stroke. Am J Hematol. 2001;67(3):179–82.
- 12. Webster MWI, Smith HJ, Sharpe DN, et al. Patent foramen ovale in young stroke patients. The Lancet. 1988;2(8601):11–12.
- Hsu L, Files B, Vichinsky E, et al. 1998 Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N. Engl. J. Med 339:5–11Robbins textbook of basic pathology.
- Rees DC, Dick MC, Height SE, O'Driscoll S, Pohl KR, Goss DE, et al. A simple index using age, hemoglobin, and aspartate transaminase predicts increased intracerebral blood velocity as measured by transcranial Doppler scanning in children with sickle cell anemia. Pediatrics. 2008;121(6):e1628–32.
- Pavlakis SG, Rees RC, Huang X, Brown RC, Casella JF, Iyer RV, et al. TCD velocities transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer. 2010;54(2):256–9
- Cox SE, Makani J, Soka D, L'Esperence VS, Kija E, Dominguez-Salas P, et al. Haptoglobin, alpha-thalassaemia and glucose-6-phosphate dehydrogenase polymorphisms and

risk of abnormal transcranial Doppler among patients with sickle cell anaemia in Tanzania. Br J Haematol. 2014;165(5):699–706.

- Kirkham FJ. Is there a genetic basis for pediatric stroke? Current Opinion in Pediatrics. 2003;15(6):547–558.
- Kwiatkowski JL, Yim E, Miller S, Adams RJ, STOP 2 Study Investig. 2011 Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr. Blood Cancer 56:777–82
- Meier ER, Wright EC, Miller JL. 2014 Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the Cooperative Study of Sickle Cell Disease. Am. J. Hematol 89:904–6 [PubMed: 24891147]
- Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. 1992 Stroke in a cohort of patients with homozygous sickle cell disease. J. Pediatr 120:360–66 [PubMed: 1538280]
- Belisario AR, Sales RR, Toledo NE, Muniz MB, Velloso-Rodrigues C, et al. 2016 Reticulocyte count is the most important predictor of acute cerebral ischemia and high-risk transcranial Doppler in a newborn cohort of 395 children with sickle cell anemia. Ann. Hematol 95:1869
- Balkaran B, Ghar G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. Journal of Pediatrics. 1992;120(3):360– 366. [PubMed] [Google Scholar]
- Lagunju I, Sodeinde O, Brown B, Akinbami F, Adedokun B. Transcranial Doppler ultrasonography in children with sickle cell anemia: clinical and laboratory correlates for elevated blood flow velocities. J Clin Ultrasound. 2014;42(2): 89–95.
- Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. 1988 Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI. Neurology 38:1012–17 [PubMed: 3386816]
- Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, et al. 2001 Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J. Pediatr 139:385–90.